U.S. markets open in 2 hours 5 minutes
  • S&P Futures

    -7.25 (-0.19%)
  • Dow Futures

    -35.00 (-0.11%)
  • Nasdaq Futures

    -28.25 (-0.21%)
  • Russell 2000 Futures

    -11.70 (-0.51%)
  • Crude Oil

    +0.14 (+0.23%)
  • Gold

    +4.60 (+0.27%)
  • Silver

    -0.30 (-1.12%)

    -0.0030 (-0.25%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Vix

    -4.75 (-16.99%)

    -0.0001 (-0.01%)

    +0.2100 (+0.20%)

    +979.66 (+2.05%)
  • CMC Crypto 200

    -5.52 (-0.56%)
  • FTSE 100

    +40.72 (+0.62%)
  • Nikkei 225

    -255.33 (-0.86%)

Pfizer, GSK-Backed ViiV First To Get FDA Approval For HIV Shots: What You Need To Know

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Shivdeep Dhaliwal
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration.

What Happened: The injectable — Cabenuva — is designed to replace the current treatment of HIV in adults which is based on taking daily pills.

Cabenuva is a Cabotegravir and Rilpivirine formulation. The treatment is meant for those patients who are on a stable antiretroviral regimen with no history of treatment failure and no known or suspected resistance to the two drugs.

The agency also approved Cabotegravir — sold under the brand name Vocabria, which should be taken in combination with Edurant (rilpivirine) for a month prior to starting treatment with the injectable.

“This approval will allow some patients the option of receiving once-monthly injections in lieu of a daily oral treatment regimen,” John Farley, director of the Office of Infectious Diseases in the FDA’s Center for Drug Evaluation and Research, said in a statement.

Why It Matters: Both Cabenuva and Vocabria — made by United Kingdom’s ViiV Healthcare, were granted fast track and priority review designation by the FDA.

Last month, the company bagged the European Union’s marketing authorization for its HIV injections and tablets.

A ViiV spokesperson said that the treatment would be made available at no charge to patients, even though it costs $47,500 a year, reported Stat News.

See Also: HIV Diagnoses Are Falling

Rival Gilead Sciences (NYSE: GILD) which also makes HIV drugs generated $17.2 billion in revenue from such treatments and grabbed 80% of the market share.

Cowen analyst Phil Nadeau expects HIV medication sales to bring in $24.4 billion in 2025.

Price Action: GSK shares closed nearly 0.6% lower at $37.38 on Thursday in New York. On the same day, Pfizer shares closed mostly unchanged at $36.48 and fell 0.16% in the after-hours session.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.